Potential anti-Parkinson drugs designed by receptor mapping.
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000978:Antiparkinson Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D001665:Binding Sites; D004298:Dopamine / Q000494:pharmacology; D007192:Indenes / Q000138:chemical synthesis* / Q000494:pharmacology; D051379:Mice; D008954:Models, Biological; D008968:Molecular Conformation; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009281:Naphthalenes / Q000138:chemical synthesis* / Q000494:pharmacology; D010095:Oxotremorine / Q000037:antagonists & inhibitors; D011804:Quinolines / Q000138:chemical synthesis* / Q000494:pharmacology; D011955:Receptors, Drug; D013329:Structure-Activity Relationship
D000700:Analgesics; D000978:Antiparkinson Agents; D007192:Indenes; D008996:Monoamine Oxidase Inhibitors; D009281:Naphthalenes; D011804:Quinolines; D011955:Receptors, Drug; D010095:Oxotremorine; D004298:Dopamine